Volume 25, Number 12—December 2019
Research
Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
Affan Shoukat, Thomas Vilches, and Seyed M. Moghadas
Table
Highest values of VCPI (in 2015 US dollars) for a Zika virus vaccine candidate to be cost-saving, very cost-effective, or cost-effective*
| Country | Herd immunity, % | Cost-saving, VCPI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Very cost-effective |
Cost-effective |
||||||||||
| GDP | VCPI | ICER | 95% CI | 3×GDP | VCPI | ICER | 95% CI | ||||
| Belize | 21 | $18 | $4,955 | $23 | $3,516 | $144–$4,575 | $14,865 | $34 | $12,092 | $7,379–$15,050 | |
| Bolivia | 10 | $22 | $3,097 | $27 | $1,827 | $(872)–$2,669 | $9,291 | $36 | $7,038 | $4,249–$9,745 | |
| Brazil | 18 | $14 | $8,694 | $21 | $6,356 | $1,596–$7,223 | $26,082 | $38 | $21,725 | $14,938–$27,441 | |
| Colombia | 12 | $16 | $5,900 | $23 | $4,184 | $1,284–$5,349 | $17,700 | $35 | $14,086 | $9,447–$16,736 | |
| Costa Rica | 2 | $10 | $11,563 | $16 | $7,352 | $1,280–$9,234 | $34,689 | $29 | $29,061 | $15,459–$30,561 | |
| Ecuador | 8 | $24 | $6,084 | $32 | $4,451 | $1,343–$5,560 | $18,252 | $48 | $15,581 | $10,338–$17,576 | |
| El Salvador | 16 | $22 | $3,719 | $26 | $1,379 | $(1,884)–$2,826 | $11,157 | $34 | $8,177 | $3,408–$9,785 | |
| French Guiana | 18 | $23 | $18,036 | $47 | $14,475 | $10,016–$16,653 | $54,108 | $96 | $49,934 | $36,523–$53,661 | |
| Guatemala | 14 | $25 | $4,032 | $32 | $2,544 | $148–$3,944 | $12,096 | $45 | $9,786 | $6,556–$11,859 | |
| Guyana | 15 | $18 | $4,325 | $23 | $2,270 | $(285)–$3,717 | $12,975 | $33 | $10,034 | $5,884–$12,262 | |
| Honduras | 14 | $21 | $2,358 | $23 | $892 | $(1,711)–$1,705 | $7,074 | $29 | $4,992 | $1,623–$6,142 | |
| Mexico | 5 | $17 | $8,867 | $26 | $6,362 | $2,564–$7,445 | $26,601 | $44 | $21,652 | $14,717–$24,875 | |
| Nicaragua | 17 | $16 | $2,109 | $18 | $595 | $(1,465)–$1,231 | $6,327 | $24 | $4,829 | $2,395–$6,068 | |
| Panama | 15 | $25 | $14,009 | $43 | $11,001 | $7,016–$13,486 | $42,027 | $82 | $37,247 | $29,096–$43,898 | |
| Paraguay | 17 | $19 | $4,094 | $23 | $2,348 | $(305)–$3,332 | $12,282 | $32 | $9,903 | $5,028–$10,670 | |
| Peru | 4 | $16 | $6,042 | $22 | $4,332 | $1,087–$4,870 | $18,126 | $35 | $14,028 | $9,262 –$16,432 | |
| Suriname | 22 | $14 | $7,298 | $21 | $4,434 | $1,505–$6,235 | $21,894 | $37 | $18,705 | $12,714–$22,331 | |
| Venezuela | 19 | $21 | $7,766 | $29 | $4,697 | $623–$6,590 | $23,298 | $47 | $19,170 | $13,160–$23,579 | |
*Mean ICER values with 95% CI correspond to VCPI values under which the vaccination program is at least 90% cost-effective in each country. The per capita GDP and 3 times the per capita GDP were used as thresholds for very cost-effective and cost-effective analyses, respectively. The dollar values in parentheses indicate that the 95% CI extends to negative ICER values, which is considered cost-saving. GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; VCPI, vaccination cost per individual.
Page created: November 18, 2019
Page updated: November 18, 2019
Page reviewed: November 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.